Generic cyclosporine formulations: more open questions than answers (Q36073209)

12 August 2017

1 reference

title

Generic cyclosporine formulations: more open questions than answers (English)

1 reference

12 August 2017

1 reference

Giuseppe Remuzzi

3

0 references

Dario Cattaneo

series ordinal

1

object named as

Dario Cattaneo

1 reference

12 August 2017

2

Norberto Perico

1 reference

12 August 2017

1 April 2005

1 reference

12 August 2017

Transplant International

1 reference

12 August 2017

18

1 reference

12 August 2017

4

1 reference

12 August 2017

371-378

1 reference

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation.

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

21 January 2018

Digoxin bioavailability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Clinical pharmacokinetic registration file for NDA and ANDA procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: bioequivalence of the new Sigmasporin Microoral and Sandimmun Neoral

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Equoral, new cyclosporine drug delivery system, versus neoral: a bioequivalence study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Bioequivalence criteria for cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Effect of bile on cyclosporin absorption in liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Administration diluents differentiate Neoral from a generic cyclosporine oral solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Neoral-to-Gengraf conversion in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Decreased oral availability of cyclosporin A at second administration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2005.00078.X

10.1111/J.1432-2277.2005.00078.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15773953